Finch Therapeutics Group, Inc. has filed for bankruptcy, along with three related companies. The Boston-based company’s decision comes after a 95% workforce reduction in 2023. The biotechnology company plans to restructure its debts while continuing operations under court supervision.
Finch Therapeutics Group, Inc. Files for Chapter 11
The company voluntarily entered the proceedings on March 22, 2026. Case records are available on PACER. Filing details show that the Chapter 11 petition was submitted in the U.S. Bankruptcy Court for the District of Delaware.
Attorney Robert A. Weber of Chipman Brown Cicero & Cole, LLP, is the company’s legal representative in the case. In addition, Matthew P. Blischak, the chief executive officer of Finch Therapeutics Group, is the authorized representative who signed the petition before it was filed.
Filing details indicate that three company affiliates, including Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC, and Finch Research and Development LLC, have also filed for bankruptcy.
Company Background
Finch Therapeutics Group, Inc. develops treatments based on beneficial gut bacteria and maintains a portfolio of microbiome-based therapies. The Boston-based company maintains a portfolio of several microbiome-based treatments. These comprise more than 70 patents in the U.S. and other nations.
Bankruptcy Follows a Major Layoff
In a news release shared on January 24, 2023, GlobeNewswire said that Finch Therapeutics Group, Inc. was set to reduce its workforce by 95%.
At that time, most employees were expected to leave the company by February 2023. The remaining employees were projected to leave the biotech company by May, after wrapping up operations and finding ways to generate value from the assets left behind.
This layoff decision was part of a broader transition at Finch Therapeutics Group, Inc. The company was then exploring ways to end the clinical trial of its drug CP101. It took a step during the last stage of the drug, which was being tested for treating C. difficile, a severe gut infection.
The company then cited a lack of funding sources and partners, misuse of its IP, delays in patient enrollment for the trial, and challenging industry conditions.
Case Related Details
RK Consultants reports that Finch Therapeutics Group, Inc. has between one and 49 creditors. Court filings indicate that funds will be available for distribution to the unsecured creditors. Further information listed in the Chapter 11 petition is:
- Filing Date: March 22, 2026
- Court and Jurisdiction: U.S. Bankruptcy Court for the District of Delaware
- Type of Filing: Active, Voluntary Petition
- Chapter: 11
- Case Number: 26-10409
- Estimated Assets: $1,000,001-$10 million
- Estimated Liabilities: $0-$50,000
- Reason for Filing: Restructure business under court supervision
The documents submitted by the biotechnology company to the court were Schedule 1 (mentioning the affiliated debtors) and an omnibus written consent of all the involved entities that filed for Chapter 11.
The company also submitted a list of creditors who have the 20 largest unsecured claims and are not insiders. Some of these creditors are Morgan Lewis & Bockius LLP, Blue Planet Supply, LLC, Iron Mountain, and Anderson & Kreiger, LLP.
Other filings by the company included a consolidated corporate ownership statement and a list of equity holders.
The Chapter 11 filing marks a notable point for Finch Therapeutics Group, Inc. as it seeks to reorganize operations amid an existing financial strain.
